Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.Explore and learn more about Conference Series : World's leading Event Organizer
As per available reports about 101 relevant journals, 28 Conferences, 28 workshops are presently dedicated exclusively to Drug Labelling and about 5000articles are being published on Drug Labelling
Drug Labeling current methods of naming, labelling, and packaging drug products are based on long-standing commercial considerations and bureaucratic procedures that tend to be insensitive to safety interests. These processes, which can appear arcane to outsiders, have been developed over a long period, are supported by substantial vested interests, and tend to resist change. It is enlisted in Pharmacological Sciences, Ethics in Pharmacy, Current GMP Guidelines, Quality Control.
OMICS International Organizes 1000+ Global Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The conference series website will provide you list and details about the conference organize worldwide.
Scope and Importance:
Two key facts drive the pharmaceutical industry's approach to naming and labeling issues. First, the longer it takes from the date of patent issuance to the date a new drug is released for marketing, the fewer the number of years of sole ownership during which the manufacturer can maximize the return on its investment. All the time preceding FDA approval represents potential lost income to the company. Therefore, companies work to shorten the regulatory process and tend to vigorously oppose any new regulatory hurdle.
Current methods of naming, labelling, and packaging drug products are based on long-standing commercial considerations and bureaucratic procedures that tend to be insensitive to safety interests. These processes, which can appear arcane to outsiders, have been developed over a long period, are supported by substantial vested interests, and tend to resist change.
Two key facts drive the pharmaceutical industry's approach to naming and labelling issues. First, the longer it takes from the date of patent issuance to the date a new drug is released for marketing, the fewer the number of years of sole ownership during which the manufacturer can maximize the return on its investment. All the time preceding FDA approval represents potential lost income to the company. Therefore, companies work to shorten the regulatory process and tend to vigorously oppose any new regulatory hurdles.
Second, a company's investment in a new drug is significant and risky. Discovering and developing new drugs is difficult and expensive -- again, creating incentives to shorten and simplify the process wherever possible. Many different molecules must be synthesized to produce just one approved drug. Even after a company obtains a patent, the probability that a marketable drug will result is only 1-2%.
In the early to mid-1990s, the average number of new drug patents was 2237 per year. Of these, 500-700 were given United States Adopted Names (USAN) generic names. Of that group, only 220 drugs were in clinical trials in 1995. From 1991 to 1996, FDA approved an average of 31 new drugs per year.
In response to manufacturer and congressional pressure to expedite and simplify the process, the number of drug approvals has been increasing steadily. In 1998, FDA approved 90 new drugs, 30 new molecular entities (drugs never previously marketed in the United States), 124 new or expanded uses of approved drugs, 344 generic drugs, 8 non-prescription drugs, and 9 orphan drugs.4 Approximately 48% of the prescription drugs marketed today have been available only since 1990, contributing to the risk of error.
Market Analysis:
In the early to mid-1990s, the average number of new drug patents was 2237 per year. Of these, 500-700 were given United States Adopted Names (USAN) generic names. Of that group, only 220 drugs were in clinical trials in 1995. From 1991 to 1996, FDA approved an average of 31 new drugs per year. In response to manufacturer and congressional pressure to expedite and simplify the process, the number of drug approvals has been increasing steadily. In 1998, FDA approved 90 new drugs, 30 new molecular entities (drugs never previously marketed in the United States), 124 new or expanded uses of approved drugs, 344 generic drugs, 8 non-prescription drugs, and 9 orphan drugs.4 Approximately 48% of the prescription drugs marketed today have been available only since 1990, contributing to the risk of error.
International symposium and workshops
List of Best International Conferences:
Relevant Society and Associations
Companies
This page will be updated regularly.
This page was last updated on April 19, 2024